FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207066013> ?p ?o ?g. }

• W4207066013 abstract "Dear Editor, For the first time to our knowledge, we describe a bimodal phenotype of coronavirus disease 2019 (COVID-19) patients provided by clinical and pathological correlation and multidisciplinary discussion, characterized by thrombotic and fibrotic poles (Figure 1). Patients with COVID-19 may present various symptoms leading to different clinical complications and outcomes, ranging from mild to severe.1, 2 Differences in these outcomes can be attributed to a differential host response to infection with variable viral load, age, gender, comorbidities, genetic and immune background. While different studies have stratified heterogenous COVID-19 patients based on different strategies,3 the characterization of histopathological patterns in association with clinical outcome of patients who died from COVID-19 remains largely unreported. We hypothesized that COVID-19 could lead to different lung injury/repair mechanisms related to different clinical and ventilatory manifestations. Therefore, we aimed to assess whether a clinical and pathological correlation could explain the different clinical outcomes among COVID-19 patients with commonly associated long-term lung dysfunction. To answer our question, we performed 47 consecutive COVID-19 patients minimally invasive autopsies followed by lung morphological analysis and clinical and radiological evaluation (Supporting information Tables S1-S4). A detailed description of the methodology can be found in the Supporting information. After a multidisciplinary discussion and data integration, we discovered a bimodal clinical and pathological phenotype presented as poles, not groups (Figure 1A; Supporting information Tables S5-S9): (1) Fibrotic phenotype (N = 5)—characterized by a progressive decline in PaO2/FiO2 ratio (Figure 1B) with low compliance levels during hospitalization (Supporting information Table S5) and alveolar septal thickening with myxoid fibrosis typical to an organizing phase of diffuse alveolar damage (DAD) (Figure 1C; Supporting information Table S6); and (2) Thrombotic phenotype (N = 10)—characterized by a progressive increase in PaO2/FiO2 ratio (Figure 1D) with high pulmonary compliance levels during hospitalization (Supporting information Table S5) and recovery of the acute/sub-acute lung injury or slight distortion of the underlying lung parenchyma architecture with a high frequency of thrombosis (80%) (Figure 1E; Supporting information Table S6). Additionally, although symptoms, signs, demographics, or comorbidities did not correlate to the phenotypes (Supporting information Table S7), d-dimer and platelets count was higher in these thrombotic patients than fibrotic ones (Supporting information Figure S1A and B and Table S8). The fibrotic phenotype results from the imbalance between myofibroblastic activation and further deposition/degradation of the collagen and elastic fibers to cause alveolar septal thickening (Figure 2), as reported in other studies.4, 5 All these features were highlighted in fibrotic phenotype compared to thrombotic one, as follows: (1) higher active myofibroblasts α-SMA area fraction (Figure 2A and B); (2) higher α-SMA and MMP-2 expression (Figure 2C and D); (3) increased extracellular matrix deposition by types I and III collagen fibers by Picrosirius Red staining (Figure 2E and F); and (4) reduced elastic fibers area fraction by Verhöeff staining (Figure 2G and H), correlating negatively to α-SMA (r = −0.57; p = 0.035; Supporting information Figure S2A). This dysfunctional alveolar septal thickening in the fibrotic phenotype impairs adequate lung function and gas exchange, which is reflected by the suggestive correlation between collagen fibers deposition and PaO2/FiO2 ratio (r = −0.64; p = 0.019; Supporting information Figure S2B and C) and significant negative correlation between compliance and drive pressure (r = −0.67; p = 0.001; Supporting information Figure 2D). According to other studies,6, 7 these patients presented a progressive decline in PaO2/FiO2 ratio (Figure 1B) and low compliance levels during hospitalization (Supporting information Table S5), suggesting a poor clinical outcome. Moreover, fibrotic phenotype patients showed neutrophil extracellular traps to a significantly greater extent throughout lung parenchyma compared to thrombotic phenotype patients (p = 0.0004) (Supporting information Figure S3), which is a crucial response during the acute COVID-19 phase and a potential contributory factor to later fibrotic phase by amplifying the chronic reparative phase.8 Conversely, patients from the thrombotic phenotype showed an unexpected progressive increase in PaO2/FiO2 ratio (Figure 1D), correlating to d-dimer levels (r = 0.37; p = 0.032; Supporting information Figure 2E) and high pulmonary compliance levels (Supporting information Table S5) correlating to elastic fibers (r = 0.57; p = 0.042; Supporting information Figure S2F), as also surprisingly reported in Gattinoni et al.9 This may be justified by the gradual recovering of the acute/sub-acute lung injury (Figure 1E) with an increased area fraction of elastic fibers (Figure 2G and H). Nevertheless, sudden death occurred, probably due to higher frequency (80%) of pulmonary thromboembolism (Supporting information Table S6), equally described in other study.10 As expected, d-dimer levels and platelet counts were higher in these patients than in fibrotic phenotype subjects (Supporting information Figure S1A and B and Table S8). Besides those two crucial phenotypes in opposite poles, it is essential to mention that 32 patients (68%) had a mixed pattern of lung injury appearing as a non-bimodal phenotype, with some overlapping of histopathological findings (Figure 1A). Thus, the pathophysiology of these patients probably represents different stages of viral lung injury with both features of acute/sub-acute and fibrotic/organizing lung injury at variable degrees. Regardless of the phenotypes, upon viral insult to the airways and bronchial epithelial cells, severe lymphocytic bronchiolitis occurs, promoting epithelial injury and cell death, eventually resulting in structural disarray by airway-centered remodeling (Figure 3). The aggressive airway wall infection then spreads to the lung parenchyma, inducing cellular pneumonitis and damaging the alveolar-capillary barrier (Figure 3, yellow arrow). This could promote DAD, bronchiolocentric alveolar hemorrhage, or fibroblastic plug, called organizing pneumonia (OP), associated or not with fibrin balls, known as acute fibrinous and OP (Figure 3). These pathophysiological processes in COVID-19 tend to happen more slowly and gradually when compared to H1N1,11 around 15 to 20 days, as shown in our cohort (Supporting information Table S1). Therefore, the longer disease progression could give histopathological basis for an organizing phase, with sustained myofibroblastic proliferation, interstitial scarring and parenchymal remodeling, representing the “birth” of fibrosis as a future and possible sequel in post-COVID-19 patients, called as the fibrotic phenotype; or gradual recovery of the acute/sub-acute lung injury associated with thrombosis and unexpected sudden death, called as thrombotic phenotype (Figures 1 and 3). Consequently, the reported sudden deaths of COVID-19 patients in clinical improvement and the description of post-COVID-19 tomographic fibrotic changes may be justified respectively by thrombotic and fibrotic phenotypes.12 Two COVID-19 patients’ follow-up with transbronchial biopsies, performed at 3 to 5 months post-infection, demonstrated lung parenchyma remodeling with alveolar septal thickening by dense fibrosis (Supporting information Figure S4). The present study presents a unique histopathological analysis of 47 COVID-19 autopsy cases with clinical and pathological correlation. We cannot disregard some limitations due to our sample size, as 47 cases are too few to establish ground rules for COVID-19 outcomes. Nevertheless, our samples are exceptional and should be valued. In conclusion, we believe that the categorization of patients based on these two phenotypes can be used to develop prognostic tools and potential therapies since the PaO2/FiO2 ratio and d-dimer correlate with the underlying fibrotic or thrombotic pathophysiologic process, which may indicate the possible clinical outcome of the patient. The authors would like to thank the institutional support of the University Hospital of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil–HCFMRP/USP. The authors declare no conflict of interest. The procedures followed in the study were approved by the National Ethics Committee–Brazil (CAAE: 32475220.5.0000.5440). The written informed consent was waived. Additional supporting information for methodology may be found online in the Supporting File. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W4207066013 created "2022-01-26" @default.
• W4207066013 creator A5004430108 @default.
• W4207066013 creator A5006216810 @default.
• W4207066013 creator A5009523234 @default.
• W4207066013 creator A5020781519 @default.
• W4207066013 creator A5026159894 @default.
• W4207066013 creator A5028869508 @default.
• W4207066013 creator A5030133110 @default.
• W4207066013 creator A5031690868 @default.
• W4207066013 creator A5036583809 @default.
• W4207066013 creator A5036654833 @default.
• W4207066013 creator A5037901279 @default.
• W4207066013 creator A5039847236 @default.
• W4207066013 creator A5041976076 @default.
• W4207066013 creator A5042386818 @default.
• W4207066013 creator A5042762358 @default.
• W4207066013 creator A5044375828 @default.
• W4207066013 creator A5044460874 @default.
• W4207066013 creator A5044706294 @default.
• W4207066013 creator A5045955094 @default.
• W4207066013 creator A5049671045 @default.
• W4207066013 creator A5050278072 @default.
• W4207066013 creator A5053727929 @default.
• W4207066013 creator A5065549226 @default.
• W4207066013 creator A5069731353 @default.
• W4207066013 creator A5070888405 @default.
• W4207066013 creator A5073885212 @default.
• W4207066013 creator A5076883931 @default.
• W4207066013 creator A5078765495 @default.
• W4207066013 creator A5082227062 @default.
• W4207066013 creator A5083390606 @default.
• W4207066013 creator A5087186890 @default.
• W4207066013 creator A5091102184 @default.
• W4207066013 creator A5091313128 @default.
• W4207066013 date "2022-01-01" @default.
• W4207066013 modified "2023-09-27" @default.
• W4207066013 title "COVID‐19 bimodal clinical and pathological phenotypes" @default.
• W4207066013 cites W2046741020 @default.
• W4207066013 cites W3012195391 @default.
• W4207066013 cites W3013176450 @default.
• W4207066013 cites W3015269808 @default.
• W4207066013 cites W3020655133 @default.
• W4207066013 cites W3027401801 @default.
• W4207066013 cites W3046031042 @default.
• W4207066013 cites W3085958090 @default.
• W4207066013 cites W3090129013 @default.
• W4207066013 cites W3104639833 @default.
• W4207066013 cites W3118737008 @default.
• W4207066013 cites W3157343612 @default.
• W4207066013 doi "https://doi.org/10.1002/ctm2.648" @default.
• W4207066013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35075808" @default.
• W4207066013 hasPublicationYear "2022" @default.
• W4207066013 type Work @default.
• W4207066013 citedByCount "5" @default.
• W4207066013 countsByYear W42070660132022 @default.
• W4207066013 countsByYear W42070660132023 @default.
• W4207066013 crossrefType "journal-article" @default.
• W4207066013 hasAuthorship W4207066013A5004430108 @default.
• W4207066013 hasAuthorship W4207066013A5006216810 @default.
• W4207066013 hasAuthorship W4207066013A5009523234 @default.
• W4207066013 hasAuthorship W4207066013A5020781519 @default.
• W4207066013 hasAuthorship W4207066013A5026159894 @default.
• W4207066013 hasAuthorship W4207066013A5028869508 @default.
• W4207066013 hasAuthorship W4207066013A5030133110 @default.
• W4207066013 hasAuthorship W4207066013A5031690868 @default.
• W4207066013 hasAuthorship W4207066013A5036583809 @default.
• W4207066013 hasAuthorship W4207066013A5036654833 @default.
• W4207066013 hasAuthorship W4207066013A5037901279 @default.
• W4207066013 hasAuthorship W4207066013A5039847236 @default.
• W4207066013 hasAuthorship W4207066013A5041976076 @default.
• W4207066013 hasAuthorship W4207066013A5042386818 @default.
• W4207066013 hasAuthorship W4207066013A5042762358 @default.
• W4207066013 hasAuthorship W4207066013A5044375828 @default.
• W4207066013 hasAuthorship W4207066013A5044460874 @default.
• W4207066013 hasAuthorship W4207066013A5044706294 @default.
• W4207066013 hasAuthorship W4207066013A5045955094 @default.
• W4207066013 hasAuthorship W4207066013A5049671045 @default.
• W4207066013 hasAuthorship W4207066013A5050278072 @default.
• W4207066013 hasAuthorship W4207066013A5053727929 @default.
• W4207066013 hasAuthorship W4207066013A5065549226 @default.
• W4207066013 hasAuthorship W4207066013A5069731353 @default.
• W4207066013 hasAuthorship W4207066013A5070888405 @default.
• W4207066013 hasAuthorship W4207066013A5073885212 @default.
• W4207066013 hasAuthorship W4207066013A5076883931 @default.
• W4207066013 hasAuthorship W4207066013A5078765495 @default.
• W4207066013 hasAuthorship W4207066013A5082227062 @default.
• W4207066013 hasAuthorship W4207066013A5083390606 @default.
• W4207066013 hasAuthorship W4207066013A5087186890 @default.
• W4207066013 hasAuthorship W4207066013A5091102184 @default.
• W4207066013 hasAuthorship W4207066013A5091313128 @default.
• W4207066013 hasBestOaLocation W42070660133 @default.
• W4207066013 hasConcept C104317684 @default.
• W4207066013 hasConcept C116675565 @default.
• W4207066013 hasConcept C127716648 @default.
• W4207066013 hasConcept C142724271 @default.
• W4207066013 hasConcept C159047783 @default.
• W4207066013 hasConcept C207886595 @default.
• W4207066013 hasConcept C2779134260 @default.
• W4207066013 hasConcept C3006700255 @default.

• next